We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Milrinone During Living Donor Hepatectomy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00966745
First Posted: August 27, 2009
Last Update Posted: August 27, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Seoul National University Hospital
  Purpose
Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Condition Intervention
Hepatectomy Drug: milrinone Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • condition of surgical field [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ]

Secondary Outcome Measures:
  • the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ]

Enrollment: 38
Study Start Date: January 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: milrinone
milrinone infusion
Drug: milrinone
Placebo Comparator: placebo Drug: placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Living liver donors

Exclusion Criteria:

  • Donors with concurrent cardiac, pulmonary, and urologic disease
  • Hepatectomy performed laparoscopically
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00966745


Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00966745     History of Changes
Other Study ID Numbers: mil_living_liver_donor
First Submitted: August 13, 2009
First Posted: August 27, 2009
Last Update Posted: August 27, 2009
Last Verified: August 2009

Keywords provided by Seoul National University Hospital:
surgical field condition

Additional relevant MeSH terms:
Milrinone
Cardiotonic Agents
Platelet Aggregation Inhibitors
Vasodilator Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs


To Top